At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
Atorvastatin injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II, Dose-ranging Study to Evaluate the Efficacy Dose Response and Pharmacokinetics of Intravenous Atorvastatin in Hypercholesterolemic Patients Previously Controlled With Oral Atorvastatin
In Brief
A Phase 2 clinical trial evaluating Atorvastatin injection for Hypercholesterolemia and Dyslipidemias. Completed, enrolled 40 participants across 1 site.
Detailed Summary
Open-label study will titrate doses of intravenous atorvastatin and monitor respective LDL-C levels in hypercholesterolemic patients previously controlled on oral atorvastatin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesterolemia, Dyslipidemias
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartAug 2018
Primary CompletionFeb 2020
Study CompletionFeb 2020
TodayJul 2026
First PostedAug 2, 2018
Enrollment StartAug 7, 2018
Primary CompletionFeb 17, 2020
Study CompletionFeb 24, 2020
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 7.9 years ago
Interventions
Atorvastatin injectiondrug
statin (i.e., 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor) for injection